Pre-Made Eftozanermin Alfa Biosimilar, Fusion Protein targeting TNFRSF10B/TRAIL-R2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD262/DR5/KILLER/KILLER/DR5/TRICK2/TRICK2A/TRICK2B/TRICKB/ZTNFR9for drug discovery and mechanism of action (MOA) research

Pre-Made Eftozanermin Alfa Biosimilar, Fusion Protein targeting TNFRSF10B/TRAIL-R2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD262/DR5/KILLER/KILLER/DR5/TRICK2/TRICK2A/TRICK2B/TRICKB/ZTNFR9is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

TRAIL (Apo2L or TNFSF10) is a member of the TNF superfamily of cytokines that play diverse roles in immune cell modulation and the activation of intracellular signaling pathways that control cell proliferation, survival, and apoptosis. TRAIL can activate cell surface death receptors, resulting in potent tumor cell death via induction of the extrinsic apoptosis pathway. Eftozanermin alfa is a second-generation TRAIL receptor agonist engineered as an IgG1-Fc mutant backbone linked to two sets of trimeric native single-chain TRAIL receptor binding domain monomers. This hexavalent agonistic fusion protein binds to the death-inducing DR4 and DR5 receptors with nanomolar affinity to drive on-target biological activity with enhanced caspase-8 aggregation and death-inducing signaling complex formation independent of FcgR-mediated crosslinking, and without clinical signs or pathologic evidence of toxicity in nonrodent species.